Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
Open Access
- 1 April 2006
- journal article
- review article
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 39 (4), 421-429
- https://doi.org/10.1590/s0100-879x2006000400001
Abstract
A high dose of delta9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of delta9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent which is devoid of the typical effects of the plant. This observation led us to suspect that CBD could have anxiolytic and/or antipsychotic actions. Studies in animal models and in healthy volunteers clearly suggest an anxiolytic-like effect of CBD. The antipsychotic-like properties of CBD have been investigated in animal models using behavioral and neurochemical techniques which suggested that CBD has a pharmacological profile similar to that of atypical antipsychotic drugs. The results of two studies on healthy volunteers using perception of binocular depth inversion and ketamine-induced psychotic symptoms supported the proposal of the antipsychotic-like properties of CBD. In addition, open case reports of schizophrenic patients treated with CBD and a preliminary report of a controlled clinical trial comparing CBD with an atypical antipsychotic drug have confirmed that this cannabinoid can be a safe and well-tolerated alternative treatment for schizophrenia. Future studies of CBD in other psychotic conditions such as bipolar disorder and comparative studies of its antipsychotic effects with those produced by clozapine in schizophrenic patients are clearly indicatedKeywords
This publication has 31 references indexed in Scilit:
- Modern antipsychotic drugs: a critical overviewCMAJ : Canadian Medical Association Journal, 2005
- Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potentialJournal of Psychopharmacology, 2005
- Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in miceEuropean Journal of Pharmacology, 2005
- Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatumLife Sciences, 2004
- Effects of Cannabidiol (CBD) on Regional Cerebral Blood FlowNeuropsychopharmacology, 2003
- Controlled clinical trial of cannabidiol in Huntington's diseasePharmacology Biochemistry and Behavior, 1991
- CANNABIS-ASSOCIATED PSYCHOSIS WITH HYPOMANIC FEATURESThe Lancet, 1982
- Interactions ofΔ 11-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentographywith cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentographyCellular and Molecular Life Sciences, 1981
- Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic PatientsPharmacology, 1980
- Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in manEuropean Journal of Pharmacology, 1974